Program
remestemcel-l
Also written as “Prochymal®”, “Remestemcel-L-rknd” and “PROCHYMAL®”.
Its studies are mostly in Graft vs Host Disease · Crohn Disease · Diabetes Mellitus, Type 1 · Pulmonary Disease, Chronic Obstructive · Myocardial Infarction, led by 2 companies.
Drug pageRemestemcel-l: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mesoblastits history only | 131 open or running | phase 3since Aug 17, 2006 | Aug 25, 2005 | Feb 28, 2028phase 3 · NCT07568535 |
| EHL Bio | 10 open or running | phase 1since Aug 15, 2016 | Aug 15, 2016 | none ahead |
Also a collaborator on its studies: Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of EHL Bio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2016First study: phase 1 study in Dermatitis, AtopicFirst studyNCT02888704 · 13 enrolled · Korea, Republic of
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study EHL Bio leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02888704Dermatitis, Atopic · Korea, Republic of | 1 | Completed | Dec 2017 | 13 |
How it is read
Names in the registry
- “Prochymal®”, 5 entries
- “Remestemcel-L-rknd”, 1 entry
- “PROCHYMAL®”, 1 entry
- “Prochymal™”, 1 entry
- “Prochymal”, 1 entry
Conditions, from the studies’ own filings
- Graft vs Host Disease, 6 studies
- Crohn Disease, 3 studies
- Diabetes Mellitus, Type 1, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
- Myocardial Infarction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.